Johnson & Johnson
Prices may be delayed up to 20 min. Not investment advice. News volume: articles about it in the 4Search index. Click a dot on the chart for the event and the news of that day.
Key statistics
Against its peers
Compare in full ›| DJNJ3.BA | JNJ.NE | LLY.NE | MRK | AZN.L | 4552.T | |
|---|---|---|---|---|---|---|
| Market cap | 4.29T | 895.29B | 1.65T | 329.65B | 208.01B | 58.57B |
| P/E (TTM) | 0.1 | 24.8 | 62.3 | 135.1 | 25.2 | — |
| Forward P/E | — | — | — | 14.9 | 15.8 | 13.1 |
| Price/book | 0.5 | 0.8 | 1.3 | 7.3 | 5.4 | 1.4 |
| Dividend yield | 2.93% | 2.49% | 0.58% | 2.63% | 1.78% | 4.05% |
| 1-year change | −5.86% | +40.84% | +35.37% | +33.19% | −3.75% | −22.20% |
| Today | 0.00% | +1.95% | −0.23% | +0.69% | +0.81% | −2.83% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 20 min.
Latest news
All DJNJ3.BA news ›Late-breaking Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA® (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness
TREMFYA® (guselkumab) showed statistically significant improvement in disease activity on the BASDAI score versus placebo, reflecting meaningful reductions in pain, stiffness, swelling and fatigue in a Phase 4 study1,2 Guselkumab…
More from 2 other outlets
- MarketScreener Johnson & Johnson Data in Psoriatic Arthritis Shows Tremfya Is the Only Advanced Therapy to Demonstrate Mri-Confirmed Improvements in Spinal Pain and Stiffness
- @PRNewswire Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness
Dividend Roundup: Nvidia, Disney, Merck, Johnson & Johnson and more
iShares Select Dividend ETF (DVY), VYM, VIG, IDV, SDY, HDV, SCHD, DGRO, NOBL, DGRW, VIGI, RDVY, SDVY, MRK Stock, NVDA Stock, JNJ Stock, DIS Stock, , , , , , By: Jason Capul, SA News Editor This week's dividend activity included increased…
Johnson & Johnson Delivered 'Immaculate' Prostate Cancer Data at ESMO. Here's Why Investors Should Care
Johnson & Johnson's $3.05 billion Halda bet is already paying off in the clinic. Key Points Johnson & Johnson’s JNJ-6143 posted excellent results in an early-stage clinical trial. For income investors, the real story is a Dividend King…
Johnson & Johnson Seeks Expanded FDA Approval for Caplyta in Bipolar Mania
Published on 11/19/2026 at 08:53 am EST - Modified on 11/19/2026 at 08:54 am EST Johnson & Johnson has filed for expanded U.S. Food and Drug Administration approval for its Caplyta antipsychotic medication in bipolar mania. J&J said the…
Johnson & Johnson Announces First Commercial Installation of the OTTAVA Robotic Surgical System At Memorial Hermann Health System
Published on 11/19/2026 at 10:38 am EST Johnson & Johnson announced that Memorial Hermann-Texas Medical Center in Houston, Texas will be the first hospital to install the OTTAVA Robotic Surgical System, representing a major milestone in…
Johnson & Johnson Submits Supplemental New Drug Application for Caplyta in Bipolar Mania
Johnson & Johnson said Thursday it has submitted a supplemental new drug application to the US Food and Drug Administration seeking approval for Caplyta for treatment of manic or mixed episodes... Johnson & Johnson Submits Supplemental New…
Johnson & Johnson Begins Ottava Surgical Robot Rollout With First Hospital Installation in Texas
Add as preferred source © Adobe Stock Images Johnson & Johnson (NYSE:JNJ) announced that Memorial Hermann-Texas Medical Center in Houston, Texas, will become the first hospital to install its Ottava robotic surgical system, marking the…
Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study
New Brunswick, N.J. (November 10, 2026) – Johnson & Johnson (NYSE: JNJ) today announced that Study 452, the second pivotal Phase 3 study evaluating CAPLYTA (lumateperone) for the treatment of manic episodes with or without mixed features…
Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
Johnson & Johnson's diversified MedTech and pharma mix faces off against Vertex's cystic fibrosis dominance, but their valuation gap tells a story worth weighing. By Brendan Coffey – Nov 17, 2026 at 6:27PM EST Key Points Johnson & Johnson…
Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenue
J&J's quarterly sales have climbed with few setbacks, while Pfizer's have swung between $13.7 billion and $17.8 billion over eight quarters. By Brendan Coffey – Nov 17, 2026 at 1:30PM EST Key Points Johnson & Johnson currently exhibits a…
From the 4Search news index, newest first.
In the news
Mentioned with
Most coverage from
- marketscreener.com27
- fool.com11
- themarketsdaily.com9
- trefis.com7
- defenseworld.net6
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 107 articles, not a forecast.